EUVIMEDEUVIMED entdecken
Open Access

Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer

Maria J Monroy-Iglesias iD, Kelli O'Connell, Jenna Bhimani, Victoria S Blinder, Rachael P Burganowski-Doud, Isaac J Ergas iD, Grace B Gallagher iD, Jennifer J Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H Kroenke iD und 13 weitere

Cancer · 2026

DOI: 10.1002/cncr.70294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Maria J Monroy-Iglesias und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Drug Tapering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Geoffrey Beene Cancer Research Center, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For most cytotoxic drugs, guidelines recommend body‐surface‐area–based dosing, yet some patients start with reduced doses, potentially reflecting tolerability concerns. The relationship between first‐cycle dose reductions and subsequent delivery is unclear.

Methods

The authors analyzed data from women with stage I–IIIA breast cancer treated with adjuvant chemotherapy. Sankey diagrams illustrated trajectories from first‐cycle dose proportion (FCDP) to average relative dose intensity (ARDI, ratio of received to expected dose intensity across the regimen), and cumulative dose proportion (CDP, ratio of total received to expected dose). Poisson regression estimated adjusted prevalence ratios for reduced FCDP (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDrug TaperingHumansFemaleNeoplasm StagingMiddle AgedChemotherapy, AdjuvantAgedAdultDose-Response Relationship, DrugBody Mass IndexErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

adjuvant chemotherapybreast cancerchemotherapy dose reductionstreatment delivery

Substanzen

Erb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
  • Division of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
  • Division of Hematology/Oncology, Department of Medicine, Department of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Oncology, Kaiser Permanente Medical Center, Vallejo, California, USA.

ORCID-Profile: Maria J Monroy-Iglesias, Isaac J Ergas, Grace B Gallagher, Candyce H Kroenke, Yashasvini Sampathkumar, Erin J Aiello Bowles, Elizabeth D Kantor

Förderung

  • NCI NIH HHS
  • Geoffrey Beene Cancer Research Center
  • National Cancer Institute

Zitieren

APA

Monroy-Iglesias, M. J., O'Connell, K., Bhimani, J., Blinder, V. S., Burganowski-Doud, R. P., Ergas, I. J., Gallagher, G. B., Griggs, J. J., Heon, N., Kolevska, T., Kotsurovskyy, Y., Kroenke, C. H., Laurent, C. A., Liu, R., Nakata, K. G., Persaud, S., Roh, J. M., Sampathkumar, Y., Tabatabai, S., …, & Kantor, E. D. (2026). Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer. Cancer. https://doi.org/10.1002/cncr.70294

Vancouver

Monroy-Iglesias MJ, O'Connell K, Bhimani J, Blinder VS, Burganowski-Doud RP, Ergas IJ, et al. Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer. Cancer. 2026. doi:10.1002/cncr.70294

BibTeX
@article{MonroyIglesias2026,
  author = {Monroy-Iglesias, Maria J and O'Connell, Kelli and Bhimani, Jenna and Blinder, Victoria S and Burganowski-Doud, Rachael P and Ergas, Isaac J and Gallagher, Grace B and Griggs, Jennifer J and Heon, Narre and Kolevska, Tatjana and Kotsurovskyy, Yuriy and Kroenke, Candyce H and Laurent, Cecile A and Liu, Raymond and Nakata, Kanichi G and Persaud, Sonia and Roh, Janise M and Sampathkumar, Yashasvini and Tabatabai, Sara and Valice, Emily and Wang, Peng and Aiello Bowles, Erin J and Bandera, Elisa V and Kushi, Lawrence H and Kantor, Elizabeth D},
  title = {Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70294}
}
Kostenlos starten →